Cargando…
FAK inhibition alone or in combination with adjuvant therapies reduces cancer stem cell activity
Cancer stem-like cells (CSC) contribute to therapy resistance and recurrence. Focal adhesion kinase (FAK) has a role in CSC regulation. We determined the effect of FAK inhibition on breast CSC activity alone and in combination with adjuvant therapies. FAK inhibition reduced CSC activity and self-ren...
Autores principales: | Timbrell, Simon, Aglan, Hosam, Cramer, Angela, Foden, Phil, Weaver, David, Pachter, Jonathan, Kilgallon, Aoife, Clarke, Robert B., Farnie, Gillian, Bundred, Nigel J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8163772/ https://www.ncbi.nlm.nih.gov/pubmed/34050172 http://dx.doi.org/10.1038/s41523-021-00263-3 |
Ejemplares similares
-
Combined Inhibition of ErbB1/2 and Notch Receptors Effectively Targets Breast Ductal Carcinoma In Situ (DCIS) Stem/Progenitor Cell Activity Regardless of ErbB2 Status
por: Farnie, Gillian, et al.
Publicado: (2013) -
Primary ductal carcinoma in situ mammosphere formation: importance of the epidermal growth factor and Notch receptor signalling pathways
por: Farnie, G, et al.
Publicado: (2008) -
Comparison of Local Recurrence After Simple and Skin-Sparing Mastectomy Performed in Patients with Ductal Carcinoma In Situ
por: Timbrell, Simon, et al.
Publicado: (2016) -
FAK/PYK2 inhibitors defactinib and VS-4718 enhance immune checkpoint inhibitor efficacy
por: Ring, Jennifer, et al.
Publicado: (2015) -
Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity
por: Howell, Sacha J, et al.
Publicado: (2008)